文献速递结核与非结核分枝杆菌艾滋病与性传播感染细菌感染、耐药与抗菌药物

依非韦伦方案抗逆转录病毒治疗对TB/HIV共感染患者利福平及其主要代谢物药代动力学的影响

Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究纳入63例结核与HIV共感染患者,用LC-MS/MS测定利福平和25-去乙酰利福平血药浓度并作非线性混合效应模型分析,同时检测SLCO1B1和SLCO1B3基因多态性。结果显示,合用依非韦伦方案抗逆转录病毒治疗者利福平口服清除率升高140%、25-去乙酰利福平升高110%,利福平生物利用度降低,提示依非韦伦方案对利福平存在相互作用并可能影响早期杀菌活性。

要点

  • 合用依非韦伦方案者利福平口服清除率升高140%。
  • 合用依非韦伦方案者25-去乙酰利福平口服清除率升高110%。
  • 该相互作用可能影响达稳态前利福平暴露及早期杀菌活性。

核心结论

  • 依非韦伦方案抗逆转录病毒治疗对利福平存在相互作用,可能影响达稳态前利福平暴露及早期杀菌活性。

研究设计与样本

  • 研究纳入63例结核与HIV共感染患者,用LC-MS/MS测定利福平和25-去乙酰利福平血药浓度,并作非线性混合效应模型分析。
  • 患者检测了SLCO1B1的463 C>A、388 A>G、11187 G>A、rs4149015、521 T>C和1436 G>C以及SLCO1B3的334 T>G基因多态性。

主要发现

  • 一室处置模型可充分描述观察数据。
  • 合用依非韦伦方案抗逆转录病毒治疗者利福平口服清除率升高140%,25-去乙酰利福平口服清除率升高110%。
  • 合用抗逆转录病毒治疗者利福平生物利用度也降低。
  • 虽未纳入最终模型,估计SLCO1B3 334 T>G野生型携带者相对生物利用度低于突变携带者。

临床怎么用

  • 对接受依非韦伦方案抗逆转录病毒治疗的结核与HIV共感染患者,应关注利福平暴露不足的风险。
  • 该相互作用可能影响早期杀菌活性,需评估治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effects of concomitant efavirenz-based ART and genetic polymorphism on the variability in rifampicin and 25-desacetylrifampicin pharmacokinetics. PATIENTS AND METHODS: Plasma concentrations of rifampicin and 25-desacetylrifampicin from 63 patients coinfected with TB and HIV were analysed by LC-MS/MS followed by non-linear mixed-effects modelling. Patients were genotyped for SLCO1B1 (463 C>A, 388 A>G, 11187 G>A, rs4149015, 521 T>C and 1436 G>C) and SLCO1B3 (334 T>G). RESULTS: One-compartment disposition models described the observations adequately. The oral clearances of rifampicin and 25-desacetylrifampicin were 140% and 110% higher, respectively, in patients on concomitant efavirenz-based ART. Rifampicin bioavailability was also lower in patients on concomitant ART. Further, although not included in the final model, a lower relative bioavailability in carriers of WT SLCO1B3 334 T>G compared with carriers of mutations in the genotype was estimated. CONCLUSIONS: The results presented indicate both pre-systemic and systemic induction by efavirenz-based ART affecting rifampicin pharmacokinetics. The described drug-drug interaction has a clinical impact on rifampicin exposure prior to steady state and may impact the early bactericidal activity in patients on efavirenz-based ART.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sundell J, Bienvenu E, Äbelö A, et al. Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV. J Antimicrob Chemother. 2021. PMID: 34337654. doi:10.1093/jac/dkab258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。